1
|
Brinch CM, Aggerholm-Pedersen N, Hogdall E, Krarup-Hansen A. Medical Oncological Treatment for Patients with Gastrointestinal Stromal Tumour (GIST) - a Systematic Review. Crit Rev Oncol Hematol 2022; 172:103650. [PMID: 35283299 DOI: 10.1016/j.critrevonc.2022.103650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Revised: 02/11/2022] [Accepted: 03/07/2022] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND Chemotherapy is ineffective in treating patients with Gastrointestinal Stromal Tumour (GIST). However, several types of tyrosine kinase inhibitors have been investigated since the approval of imatinib in 2001. The purpose of this report was to systematically review studies on the efficacy of neoadjuvant, adjuvant, and lifelong medical oncological treatment of GIST. METHODS The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed throughout the review process. The protocol was submitted to the International prospective register of systematic reviews database (ID 251724). A systematic literature search was performed, including phase II- and III studies of biological treatment, reporting on treatment effect in patients with GIST. RESULTS Of 308 identified publications, 42 studies were included in this review. CONCLUSION This review gives an overview of the existing evidence for approved lines of oncological treatments and potential alternatives for patients with GIST in the neoadjuvant-, adjuvant- and life-long setting.
Collapse
Affiliation(s)
- Charlotte Margareta Brinch
- Department of Oncology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Borgmester Ib Juuls Vej 1, DK-2730, Herlev.
| | - Ninna Aggerholm-Pedersen
- Department of Oncology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200, Aarhus, Denmark.
| | - Estrid Hogdall
- Department of Pathology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Borgmester Ib Juuls Vej 73, DK-2730, Herlev, Denmark.
| | - Anders Krarup-Hansen
- Department of Oncology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Borgmester Ib Juuls Vej 1, DK-2730, Herlev.
| |
Collapse
|
3
|
Maurel J, López-Pousa A, de las Peñas R, Fra J, Martín J, Cruz J, Casado A, Poveda A, Martínez-Trufero J, Balañá C, Gómez MA, Cubedo R, Gallego O, Rubio-Viqueira B, Rubió J, Andrés R, Sevilla I, de la Cruz JJ, del Muro XG, Buesa JM. Efficacy of Sequential High-Dose Doxorubicin and Ifosfamide Compared With Standard-Dose Doxorubicin in Patients With Advanced Soft Tissue Sarcoma: An Open-Label Randomized Phase II Study of the Spanish Group for Research on Sarcomas. J Clin Oncol 2009; 27:1893-8. [PMID: 19273704 DOI: 10.1200/jco.2008.19.2930] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose To assess the progression-free survival (PFS) and antitumor response to standard-dose doxorubicin compared with sequential dose-dense doxorubicin and ifosfamide in first-line treatment of advanced soft tissue sarcoma. Patients and Methods Patients with measurable advanced soft tissue sarcoma, Eastern Cooperative Oncology Group (ECOG) performance status (PS) < 2, between the ages 18 and 65 years, and with adequate bone marrow, liver, and renal function were entered in the study. The stratifications were: ECOG PS (0 v 1), location of metastases, and potentially resectable disease. Patients were randomly assigned to either doxorubicin 75 mg/m2 given as a bolus injection every 3 weeks for 6 cycles (arm A) or doxorubicin at 30 mg/m2 per day for 3 consecutive days once every 2 weeks for 3 cycles followed by ifosfamide at 12.5 g/m2 delivered by continuous infusion over 5 days once every 3 weeks for 3 cycles with filgastrim or pegfilgastrim support (arm B). Results Between December 2003 and September 2007, 132 patients were entered onto the study. Febrile neutropenia, asthenia, and mucositis were more frequent in the arm B. The interim preplanned analysis for futility allowed the premature closure. Objective responses were observed in 23.4% of assessable patients in arm A and 24.1% in arm B. PFS was 26 weeks in the arm A and 24 weeks in arm B (P = .88). Overall survival did not differ between the two therapeutic arms (P = .14). Conclusion Single-agent doxorubicin remains the standard treatment in fit patients with advanced soft tissue sarcoma.
Collapse
Affiliation(s)
- Joan Maurel
- From the Medical Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Hospital Clínic Barcelona, University of Barcelona; Hospital Sant Pau, Barcelona; Hospital Provincial Castellón; Hospital Central Asturias; Hospital Universitario Canarias; Hospital Son Dureta, Mallorca; Hospital Clínico Madrid; Instituto Valenciano de Oncologia; Hospital Miguel Servet, Zaragoza; Hospital Germans Trias i Pujol,
| | - Antonio López-Pousa
- From the Medical Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Hospital Clínic Barcelona, University of Barcelona; Hospital Sant Pau, Barcelona; Hospital Provincial Castellón; Hospital Central Asturias; Hospital Universitario Canarias; Hospital Son Dureta, Mallorca; Hospital Clínico Madrid; Instituto Valenciano de Oncologia; Hospital Miguel Servet, Zaragoza; Hospital Germans Trias i Pujol,
| | - Ramón de las Peñas
- From the Medical Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Hospital Clínic Barcelona, University of Barcelona; Hospital Sant Pau, Barcelona; Hospital Provincial Castellón; Hospital Central Asturias; Hospital Universitario Canarias; Hospital Son Dureta, Mallorca; Hospital Clínico Madrid; Instituto Valenciano de Oncologia; Hospital Miguel Servet, Zaragoza; Hospital Germans Trias i Pujol,
| | - Joaquín Fra
- From the Medical Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Hospital Clínic Barcelona, University of Barcelona; Hospital Sant Pau, Barcelona; Hospital Provincial Castellón; Hospital Central Asturias; Hospital Universitario Canarias; Hospital Son Dureta, Mallorca; Hospital Clínico Madrid; Instituto Valenciano de Oncologia; Hospital Miguel Servet, Zaragoza; Hospital Germans Trias i Pujol,
| | - Javier Martín
- From the Medical Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Hospital Clínic Barcelona, University of Barcelona; Hospital Sant Pau, Barcelona; Hospital Provincial Castellón; Hospital Central Asturias; Hospital Universitario Canarias; Hospital Son Dureta, Mallorca; Hospital Clínico Madrid; Instituto Valenciano de Oncologia; Hospital Miguel Servet, Zaragoza; Hospital Germans Trias i Pujol,
| | - Josefina Cruz
- From the Medical Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Hospital Clínic Barcelona, University of Barcelona; Hospital Sant Pau, Barcelona; Hospital Provincial Castellón; Hospital Central Asturias; Hospital Universitario Canarias; Hospital Son Dureta, Mallorca; Hospital Clínico Madrid; Instituto Valenciano de Oncologia; Hospital Miguel Servet, Zaragoza; Hospital Germans Trias i Pujol,
| | - Antonio Casado
- From the Medical Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Hospital Clínic Barcelona, University of Barcelona; Hospital Sant Pau, Barcelona; Hospital Provincial Castellón; Hospital Central Asturias; Hospital Universitario Canarias; Hospital Son Dureta, Mallorca; Hospital Clínico Madrid; Instituto Valenciano de Oncologia; Hospital Miguel Servet, Zaragoza; Hospital Germans Trias i Pujol,
| | - Andrés Poveda
- From the Medical Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Hospital Clínic Barcelona, University of Barcelona; Hospital Sant Pau, Barcelona; Hospital Provincial Castellón; Hospital Central Asturias; Hospital Universitario Canarias; Hospital Son Dureta, Mallorca; Hospital Clínico Madrid; Instituto Valenciano de Oncologia; Hospital Miguel Servet, Zaragoza; Hospital Germans Trias i Pujol,
| | - Javier Martínez-Trufero
- From the Medical Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Hospital Clínic Barcelona, University of Barcelona; Hospital Sant Pau, Barcelona; Hospital Provincial Castellón; Hospital Central Asturias; Hospital Universitario Canarias; Hospital Son Dureta, Mallorca; Hospital Clínico Madrid; Instituto Valenciano de Oncologia; Hospital Miguel Servet, Zaragoza; Hospital Germans Trias i Pujol,
| | - Carmen Balañá
- From the Medical Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Hospital Clínic Barcelona, University of Barcelona; Hospital Sant Pau, Barcelona; Hospital Provincial Castellón; Hospital Central Asturias; Hospital Universitario Canarias; Hospital Son Dureta, Mallorca; Hospital Clínico Madrid; Instituto Valenciano de Oncologia; Hospital Miguel Servet, Zaragoza; Hospital Germans Trias i Pujol,
| | - María Auxiliadora Gómez
- From the Medical Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Hospital Clínic Barcelona, University of Barcelona; Hospital Sant Pau, Barcelona; Hospital Provincial Castellón; Hospital Central Asturias; Hospital Universitario Canarias; Hospital Son Dureta, Mallorca; Hospital Clínico Madrid; Instituto Valenciano de Oncologia; Hospital Miguel Servet, Zaragoza; Hospital Germans Trias i Pujol,
| | - Ricardo Cubedo
- From the Medical Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Hospital Clínic Barcelona, University of Barcelona; Hospital Sant Pau, Barcelona; Hospital Provincial Castellón; Hospital Central Asturias; Hospital Universitario Canarias; Hospital Son Dureta, Mallorca; Hospital Clínico Madrid; Instituto Valenciano de Oncologia; Hospital Miguel Servet, Zaragoza; Hospital Germans Trias i Pujol,
| | - Oscar Gallego
- From the Medical Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Hospital Clínic Barcelona, University of Barcelona; Hospital Sant Pau, Barcelona; Hospital Provincial Castellón; Hospital Central Asturias; Hospital Universitario Canarias; Hospital Son Dureta, Mallorca; Hospital Clínico Madrid; Instituto Valenciano de Oncologia; Hospital Miguel Servet, Zaragoza; Hospital Germans Trias i Pujol,
| | - Belen Rubio-Viqueira
- From the Medical Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Hospital Clínic Barcelona, University of Barcelona; Hospital Sant Pau, Barcelona; Hospital Provincial Castellón; Hospital Central Asturias; Hospital Universitario Canarias; Hospital Son Dureta, Mallorca; Hospital Clínico Madrid; Instituto Valenciano de Oncologia; Hospital Miguel Servet, Zaragoza; Hospital Germans Trias i Pujol,
| | - Jordi Rubió
- From the Medical Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Hospital Clínic Barcelona, University of Barcelona; Hospital Sant Pau, Barcelona; Hospital Provincial Castellón; Hospital Central Asturias; Hospital Universitario Canarias; Hospital Son Dureta, Mallorca; Hospital Clínico Madrid; Instituto Valenciano de Oncologia; Hospital Miguel Servet, Zaragoza; Hospital Germans Trias i Pujol,
| | - Raquel Andrés
- From the Medical Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Hospital Clínic Barcelona, University of Barcelona; Hospital Sant Pau, Barcelona; Hospital Provincial Castellón; Hospital Central Asturias; Hospital Universitario Canarias; Hospital Son Dureta, Mallorca; Hospital Clínico Madrid; Instituto Valenciano de Oncologia; Hospital Miguel Servet, Zaragoza; Hospital Germans Trias i Pujol,
| | - Isabel Sevilla
- From the Medical Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Hospital Clínic Barcelona, University of Barcelona; Hospital Sant Pau, Barcelona; Hospital Provincial Castellón; Hospital Central Asturias; Hospital Universitario Canarias; Hospital Son Dureta, Mallorca; Hospital Clínico Madrid; Instituto Valenciano de Oncologia; Hospital Miguel Servet, Zaragoza; Hospital Germans Trias i Pujol,
| | - Juan Jose de la Cruz
- From the Medical Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Hospital Clínic Barcelona, University of Barcelona; Hospital Sant Pau, Barcelona; Hospital Provincial Castellón; Hospital Central Asturias; Hospital Universitario Canarias; Hospital Son Dureta, Mallorca; Hospital Clínico Madrid; Instituto Valenciano de Oncologia; Hospital Miguel Servet, Zaragoza; Hospital Germans Trias i Pujol,
| | - Xavier García del Muro
- From the Medical Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Hospital Clínic Barcelona, University of Barcelona; Hospital Sant Pau, Barcelona; Hospital Provincial Castellón; Hospital Central Asturias; Hospital Universitario Canarias; Hospital Son Dureta, Mallorca; Hospital Clínico Madrid; Instituto Valenciano de Oncologia; Hospital Miguel Servet, Zaragoza; Hospital Germans Trias i Pujol,
| | - Jose María Buesa
- From the Medical Oncology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Hospital Clínic Barcelona, University of Barcelona; Hospital Sant Pau, Barcelona; Hospital Provincial Castellón; Hospital Central Asturias; Hospital Universitario Canarias; Hospital Son Dureta, Mallorca; Hospital Clínico Madrid; Instituto Valenciano de Oncologia; Hospital Miguel Servet, Zaragoza; Hospital Germans Trias i Pujol,
| |
Collapse
|